Fluconazole Tablet Added to DailyMed Azole Antifungal Search Results
DailyMed’s azole antifungal class search turns up a repackaged fluconazole tablet entry from Proficient Rx LP, listed with NDC codes 71205-796-01 and 71205-796-02. The label is tied to source NDC 68462-119, placing the product squarely within the federal drug-labeling system that clinicians, pharmacists, and health systems use to verify packaging, labeling lineage, and product identity.
For day-to-day prescribing, that sort of listing can appear administrative at first glance. It is not. A repackaged label still matters because the label is the point where a product’s commercial packaging, manufacturer lineage, and distribution record intersect with medication safety checks at the bedside, in the pharmacy, and inside electronic medication systems. In antifungal therapy, where oral and topical azoles may be used interchangeably in conversation but not in pharmacologic effect, precision at the label level is part of the safety net.
The DailyMed entry does not describe clinical trial outcomes, comparative efficacy, or dosing changes. It does, however, confirm that fluconazole tablet remains indexed as a branded formulation within the broader azole antifungal class search. That matters for institutions that reconcile inventory, match national drug codes to formularies, and maintain clean medication records across wholesale, repackaged, and dispensed products.
Why the Label Record Matters at the Point of Care
Fluconazole occupies a familiar place in antifungal practice because oral azole agents often serve as practical options when systemic treatment is needed and a topical agent would not be enough. The distinction is operational as much as therapeutic: a tablet on a formulary list is not interchangeable with a cream, and a repackaged label is not just a clerical variant of the original product. It is a trackable unit of medication identity.
That is especially relevant in a class search like this one, where several azole products appear side by side. In the same results set, DailyMed also lists miconazole nitrate cream 2%, ketoconazole cream, terconazole cream, and clotrimazole and betamethasone dipropionate cream. Their coexistence in the same class search is a reminder that antifungal selection depends on route, formulation, and indication, not on the class name alone.
A tablet entry carries a different clinical weight than a cream entry. Oral exposure, systemic distribution, and the downstream implications of medication reconciliation all enter the picture once the dosage form changes. For pharmacists reviewing a medication profile, the exact NDC can help confirm that the product in hand is the product intended. For prescribers, that same record helps preserve clarity when therapy is transferred between settings.
Repackaged Products and the Safety Chain
The label identifies Proficient Rx LP as the packager and specifies that this is a repackaged label. It also links back to source NDC 68462-119. Those are small details, but they are the kind that keep medication systems aligned. When a product is repackaged, the original manufacturer record and the downstream packager record both become part of the traceable history.
In real-world practice, that traceability helps reduce confusion during dispensing, formulary review, product substitution, and inventory management. It also supports the broader medication safety framework used by hospitals, community pharmacies, and long-term care facilities. A repackaged label may look ordinary on a search page, yet it can be the difference between a clean medication history and an avoidable reconciliation error.
There is no efficacy claim embedded in this DailyMed entry. No head-to-head comparison is provided, no new indication is announced, and no safety signal is attached to the listing itself. The value lies in the regulatory and informatics record: this is a recognized fluconazole tablet product, assigned specific NDCs and carried under a repackaged label structure.
What Clinicians Can Infer From the Listing Alone
The narrowest defensible reading of the record is straightforward. Fluconazole remains actively cataloged within DailyMed’s azole antifungal class results, and this specific tablet product is distributed as a repackaged item under Proficient Rx LP. For clinicians, that means the label is usable as a verification source when matching a prescription to a physical product or reconciling a medication list.
The broader clinical context is equally simple. Azole antifungals are not a single interchangeable treatment bucket. Formulation and route dictate whether a product functions as a local therapy, a systemic therapy, or something in between. A tablet listing in this search result sits in a different operational category than the topical creams that appear around it.
That distinction reaches beyond nomenclature. It affects how the product is prescribed, stocked, documented, and checked. It also explains why federal labeling databases remain essential even when the label update itself contains no dramatic headline. A clean record can prevent a messy bedside misunderstanding.
The Limits of This Update
This DailyMed search result is a labeling and distribution update, not a clinical study and not a safety bulletin. It provides product identification, NDC codes, packager information, and source linkage, but it does not provide new efficacy data, comparative outcomes, or event rates. Any clinical interpretation beyond that would go beyond the record.
What remains on the page is still clinically useful. The listing confirms that fluconazole tablet is available in a repackaged form under two NDC codes, with a defined source label behind it. For a medication class that often depends on precise matching between prescription, product, and administration record, that kind of specificity is the part that keeps antifungal therapy orderly rather than merely available.